Engineered immune cells take aim at stubborn autoimmune disease
NCT ID NCT07599280
First seen May 21, 2026 · Last updated May 21, 2026
Summary
This early-phase study tests a new cell therapy called universal STAR-T cells in people with autoimmune diseases that cause dangerously low platelet counts. About 6 adults aged 18-65 will receive a single infusion of these engineered cells to see if they are safe and can help control the disease. The goal is to find the right dose and check for side effects, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 28, Fuxing Road, Haidian District, Beijing, China.
Haidian, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.